Digirad Corporation Reports Financial Results for Second Quarter and First Six Months of 2014
- Year over year revenue growth of 13% for both periods
-
Adjusted net income improved by more than
$1.0 million and$2.7 million , respectively - Announces financial guidance for 2014
-
Announces a regular quarterly cash dividend of
$0.05 cents per share
Total revenues for the 2014 second quarter were
Total revenues for the first six months of 2014 were up 13 percent year over year to
"I am also very pleased to announce that the integration of our recent Telerhythmics acquisition is going well and as planned. We are working hard and fast to get the business fully integrated within all our sales programs and operations, as well as the back office activities. This process will take some time as we previously announced, but once complete, we believe Telerhythmics will be poised for outstanding growth."
The Company's cash, cash equivalents and available-for-sale securities balance at
Excluding the
Adjusted EBITDA for the second quarter of 2014 was
The Company also announced a cash dividend of
2014 Six-Month Financial Highlights
Net income in the first six months of 2014 improved year over year from the loss in the first six months of 2013 by more than
Adjusted net income for the first six months of 2014 was
Adjusted EBITDA for the first six months of this year was
2014 Financial Guidance
For fiscal year 2014, the Company expects to generate revenues between
The Company's non-GAAP financial measure adjusted diluted earnings per share excludes restructuring charges and acquired intangible asset amortization. Adjusted EBITDA further excludes stock-based compensation expense.
Conference Call Information
A conference call is scheduled for
Use of Non-GAAP Financial Measures by
This
A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding
About
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Some of these forward-looking statements can be identified by the use of forward-looking words such as "believes," "expects," "may," "will," "should," "seek," "approximately," "intends," "plans," "estimates," or "anticipates," or the negative of those words or other comparable terminology, or in specific statements such as the Company's ability to deliver value to customers, the ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These risks are detailed in
(Financial tables follow)
|
|
||||
| Condensed Consolidated Statements of Income (Loss) | ||||
| (Unaudited) | ||||
| Three Months Ended | Six Months Ended | |||
|
|
|
|||
| (in thousands, except per share amounts) | 2014 | 2013 | 2014 | 2013 |
| Revenues: | ||||
| Diagnostic Services |
|
|
|
|
| Diagnostic Imaging | 3,247 | 3,415 | 6,689 | 6,022 |
| Total revenues | 14,587 | 12,890 | 27,584 | 24,436 |
| Cost of revenues: | ||||
| Diagnostic Services | 8,204 | 7,179 | 15,738 | 14,004 |
| Diagnostic Imaging | 1,878 | 1,918 | 3,899 | 3,822 |
| Total cost of revenues | 10,082 | 9,097 | 19,637 | 17,826 |
| Gross profit | 4,505 | 3,793 | 7,947 | 6,610 |
| Total gross profit percentage | 30.9% | 29.4% | 28.8% | 27.1% |
| Diagnostic Services gross profit percentage | 27.7% | 24.2% | 24.7% | 23.9% |
| Diagnostic Imaging gross profit percentage | 42.2% | 43.8% | 41.7% | 36.5% |
| Operating expenses: | ||||
| Research and development | — | 177 | — | 996 |
| Marketing and sales | 1,245 | 1,009 | 2,340 | 2,245 |
| General and administrative | 2,193 | 2,571 | 4,188 | 4,673 |
| Amortization of intangible assets | 104 | 58 | 170 | 123 |
| Restructuring charges | 138 | 610 | 579 | 1,614 |
| Total operating expenses | 3,680 | 4,425 | 7,277 | 9,651 |
| Income (loss) from operations | 825 | (632) | 670 | (3,041) |
| Other income (expense): | ||||
| Interest and other income, net | 15 | 16 | 32 | 39 |
| Interest expense | (9) | (4) | (17) | (5) |
| Total other income | 6 | 12 | 15 | 34 |
| Income (loss) before income taxes | 831 | (620) | 685 | (3,007) |
| Income tax benefit (expense) | (8) | 4 | (10) | (28) |
| Net income (loss) |
|
$ (616) |
|
|
| Net income (loss) per share - basic |
|
|
|
|
| Net income (loss) per share - diluted |
|
|
|
|
| Weighted average shares outstanding - basic | 18,554 | 19,032 | 18,536 | 19,177 |
| Weighted average shares outstanding - diluted | 18,839 | 19,032 | 18,831 | 19,177 |
|
|
||
| Condensed Consolidated Balance Sheets | ||
| (Unaudited) | ||
|
|
|
|
| (in thousands, except share data) | 2014 | 2013 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents |
|
|
| Securities available-for-sale | 9,825 | 7,673 |
| Accounts receivable, net | 6,219 | 5,430 |
| Inventories, net | 3,495 | 3,881 |
| Other current assets | 422 | 697 |
| Restricted cash | 477 | 244 |
| Total current assets | 32,017 | 36,669 |
| Property and equipment, net | 4,586 | 4,153 |
| Intangible assets, net | 2,763 | 353 |
| Goodwill | 1,337 | 184 |
| Other assets | 72 | 92 |
| Total assets |
|
|
| Liabilities and stockholders' equity | ||
| Accounts payable |
|
|
| Accrued compensation | 2,555 | 3,472 |
| Accrued warranty | 155 | 137 |
| Deferred revenue | 1,478 | 1,631 |
| Other accrued liabilities | 1,868 | 1,774 |
| Total current liabilities | 7,534 | 7,625 |
| Other liabilities | 774 | 440 |
| Total liabilities | 8,308 | 8,065 |
| Stockholders' equity: | ||
| Preferred stock | — | — |
| Common stock | 2 | 2 |
| Treasury stock | (5,728) | (5,728) |
| Additional paid-in capital | 155,384 | 156,968 |
| Accumulated other comprehensive loss | (12) | (2) |
| Accumulated deficit | (117,179) | (117,854) |
| Total stockholders' equity | 32,467 | 33,386 |
| Total liabilities and stockholders' equity |
|
|
|
|
||||
| Reconciliation of Non-GAAP Financial Measures | ||||
| (Unaudited) | ||||
|
Three Months Ended |
Six Months Ended |
|||
| (in thousands, except per share amounts) | 2014 | 2013 | 2014 | 2013 |
| Total operating expenses |
|
|
|
|
| Restructuring charges(1) | (138) | (610) | (579) | (1,614) |
| Non-GAAP Adjusted operating expenses |
|
|
|
|
| Net income (loss) |
|
|
|
|
| Restructuring charges(1) | 138 | 610 | 579 | 1,614 |
| Acquired intangible amortization | 102 | 55 | 165 | 118 |
| Income tax items(2) | (2) | — | (6) | — |
| Non-GAAP Adjusted net income (loss) |
|
|
|
|
| Net income (loss) per share - diluted |
|
|
|
|
| Restructuring charges(1)(3) | 0.01 | 0.03 | 0.03 | 0.09 |
| Acquired intangible amortization(3) | 0.01 | — | 0.01 | 0.01 |
| Income tax items(2)(3) | — | — | — | — |
| Non-GAAP Adjusted net income (loss) per share - diluted(3) |
|
$ — |
|
$ (0.07) |
|
Three Months Ended |
Six Months Ended |
|||
| (in thousands) | 2014 | 2013 | 2014 | 2013 |
| Net income (loss) |
|
|
|
|
| Restructuring charges(1) | 138 | 610 | 579 | 1,614 |
| Depreciation and amortization | 485 | 479 | 938 | 972 |
| Stock-based compensation | 61 | 105 | 111 | 226 |
| Interest and other income, net | (15) | (16) | (32) | (39) |
| Interest expense | 9 | 4 | 17 | 5 |
| Income tax expense (benefit) | 8 | (4) | 10 | 28 |
| Non-GAAP Adjusted EBITDA |
|
|
|
|
|
(1) Reflects nonrecurring charges primarily related to restructuring of the Diagnostic Imaging reporting segment and lease termination of the |
||||
| (2) Reflects income tax effect for adjusted financial data. | ||||
| (3) Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and sum of individual items may not equal the total. | ||||
|
|
|||||
| Reconciliation of Non-GAAP Financial Measures | |||||
| (Unaudited) | |||||
| Three Months Ended | |||||
| (in thousands, except per share amounts) |
2013 |
2013 |
2013 |
2014 |
2014 |
| Total operating expenses |
|
|
|
|
|
| Restructuring charges(1) | (610) | (79) | (35) | (441) | (138) |
| Gain on sale of assets and license agreement(2) | — | 1,568 | — | — | — |
| Non-GAAP Adjusted operating expenses |
|
|
|
|
|
| Net income (loss) |
|
|
|
|
|
| Restructuring charges(1) | 610 | 79 | 35 | 441 | 138 |
| Gain on sale of assets and license agreement(2) | — | (1,568) | — | — | — |
| Acquired intangible amortization | 55 | 51 | 51 | 64 | 102 |
| Income tax items(3) | — | — | — | (4) | (2) |
| Non-GAAP Adjusted net income (loss) |
|
|
|
|
|
| Net income (loss) per share - diluted(4) |
|
|
|
|
|
| Restructuring charges(1)(4) | 0.03 | — | — | 0.02 | 0.01 |
| Gain on sale of assets and license agreement(2)(4) | — | (0.08) | — | — | — |
| Acquired intangible amortization | — | — | — | — | 0.01 |
| Income tax items(3)(4) | — | — | — | — | — |
| Non-GAAP Adjusted net income per share - diluted(4) | $ — |
|
|
|
|
| Three Months Ended | |||||
| (in thousands) |
2013 |
2013 |
2013 |
2014 |
2014 |
| Net income (loss) |
|
|
|
|
|
| Restructuring charges(1) | 610 | 79 | 35 | 441 | 138 |
| Gain on sale of assets and license agreement(2) | — | (1,568) | — | — | — |
| Depreciation and Amortization | 479 | 475 | 466 | 453 | 485 |
| Stock-based Compensation | 105 | 74 | 40 | 50 | 61 |
| Interest and other income, net | (16) | (13) | (11) | (17) | (15) |
| Interest expense | 4 | 5 | 5 | 8 | 9 |
| Income tax benefit (expense) | (4) | (72) | (1) | 2 | 8 |
| Non-GAAP Adjusted EBITDA |
|
|
|
|
|
|
(1) Reflects nonrecurring charges primarily related to restructuring of the Diagnostic Imaging reporting segment and lease termination of the |
|||||
| (2) Reflects a nonrecurring gain related to the sale of assets associated with an uncommercialized surgical imaging system, and the licensing of certain existing Company technology. | |||||
| (3) Reflects income tax effect for adjusted financial data. | |||||
| (4) Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and sum of individual items may not equal the total. | |||||
|
|
|
| 2014 Financial Guidance | |
| (in thousands, except per share amounts) | |
| Revenue |
|
| Adjusted diluted earnings per share(1) |
|
| Adjusted EBITDA(1) |
|
| (1) Adjusted diluted earnings per share and adjusted EBITDA are non-GAAP financial measures. The non-GAAP financial measure adjusted diluted earnings per share excludes restructuring charges and acquired intangible asset amortization. Adjusted EBITDA further excludes stock-based compensation expense. |
CONTACT:Source:Jeffry Keyes Chief Financial Officer 858-726-1600 ir@digirad.com
News Provided by Acquire Media

